| | 
Part, Chapter, Paragraph
1 I, 2. 10. 4 | medication errors being first (37.4% of such events). 10~ ~
2 I, 3. 2 | population is large (i.e. 37%). According to GCIM (2004),
3 II, 5. 2. 2 | MONICA Project assessed in 37 populations of 21 countries
4 II, 5. 2. 3 | 450 to 326 per 100.000), 37% in Central Europe countries5 (
5 II, 5. 2. 3 | to 189 per 100.000) and 37% in Central Eastern Europe (
6 II, 5. 2. 7 | mortality: 10-year results from 37 WHO MONICA project populations.
7 II, 5. 3. 5 | estimated in Macedonia for men (37 new cases per 100,000) and
8 II, 5. 4. 3 | million in 2006 to over 37 million in 2025. In 2006,
9 II, 5. 4. 3 | between 10% for Ireland and 37% for Denmark, with a median
10 II, 5. 4. 3 | reported a range between 37 (Cyprus) and 2,675 (Germany),
11 II, 5. 4. 8 | Pediatr Diabetes 8(3):117-37~Waug A (2007): Screening
12 II, 5. 5. 3 | age: 28% for 11-year-olds, 37% for 13-year-olds and 42%
13 II, 5. 5. 3 | in Spain, 41% in Finland, 37% in Italy, 35% in Denmark,
14 II, 5. 5. 3 | by generalized syndromes (37-48%) and unclassified syndromes (
15 II, 5. 5. 3 | population-based study. Epilepsia 37:224-229.~Forsgren L (2004):
16 II, 5. 5. 3 | diagnostic categories. Epilepsia 37:1051-1059.~Pazzaglia P,
17 II, 5. 5. 3 | Neurol Scand 183(Suppl):37-40.~Nicoletti A, Lo Bartolo
18 II, 5. 5. 3 | of San Marino. Neurology 37(10):1679-1682.~de Rijk MC,
19 II, 5. 5. 3 | disease. J Neurol Sci. 262:37-44.~Errea JM, Ara JR, Aibar
20 II, 5. 5. 3 | Sweden. Mov Disord. 14:28-37.~ ~Findley L, Aujla M, Bain
21 II, 5. 6. 3 | annual incidences of 9 and 37 per 10 000 men and women
22 II, 5. 8. 3 | stay in hospital was 11.37 days and the cost of treatment
23 II, 5. 8. 6 | 1%, p<0.001) or at home (37.4% vs 2.8%, p<0.05) than
24 II, 5. 9. 2 | years from 66 centres in 37 countries and 304 679 children
25 II, 5. 9. 3 | 14 years old presented a 37.1% prevalence. The other
26 II, 5. 9. 3 | visits). Drug costs make up 37% of the total direct cost
27 II, 5. 9. 7 | Clin Exp Allergy 37:780-7.~ ~Bousquet PJ, Chinn
28 II, 5. 9. 7 | and Experimental Allergy, 37, 788–79~ ~Bugiani M (2005):
29 II, 5. 11. 3 | Contact Dermatitis, 1997;37(2):78-81.~H Suzuki, Nickel
30 II, 5. 11. 3 | diagnosed world-wide and 37 000 deaths caused by melanoma.
31 II, 5. 12. 7 | in Italy. Dig Liver Dis 37:622-627.~ ~World Health
32 II, 5. 15. 6 | Cells Mol Dis. 2006 Jul-Aug;37(1):46-9. Epub 2006 Jul 7.~
33 II, 6. 3. 3 | followed by Latvia (7.37 per 100 000). Incidence
34 II, 6. 3. 6 | Germany (56 cases), France (37 cases) and Denmark (three
35 II, 7. 4. 3 | fatalities were pedestrians, 37% to motorised road users
36 II, 9. 2. 7 | 1955—1995. Eur J Cancer. 37:785-809.~ ~Masoli M, Fabian
37 II, 9. 3. 2 | ratio ranging from 0.02-37%.~ ~Severe maternal morbidity
38 II, 9. 4. 1 | the median age in the EU (37.7) will increase to 52.3
39 II, 9. 4. 7 | Trends. vol. 25, pp. 31–37.~ ~International Diabetes
40 III, 10. 2. 1 | from 15.9% in Sweden to 37.6% in Greece. Despite wide
41 III, 10. 2. 1 | countries i.e. Lithuania (37%), Latvia (48%), Hungary (
42 III, 10. 2. 1 | Journal of Adolescent Health 37:371–375.~ ~Engstrom JL,
43 III, 10. 2. 4 | University Press, pp 17-37.~ ~French ME, Moore JB (
44 III, 10. 4. 2(35)| cereals (OJ L 221, 7.8.1986, p 37).~
45 III, 10. 4. 2 | delivering conclusions on 37 active substances from list
46 III, 10. 5. 3 | Working Conditions Survey, 37% of men and 31% of women
47 III, 10. 5. 3 | organisation of working time~- 98/37/EC: machinery~- 2002/44/
48 III, 10. 5. 3 | protection of young people~- 98/37/EC: approximation of the
49 IV, 11. 6. 1 | and 2005, outpacing the 37% growth in GDP per capita.
50 IV, 11. 6. 5 | care." Medical Care Review 37(7): 653-98.~ ~Dovey SM,
51 IV, 12. 1 | derogation from Article 37, measures in the veterinary
52 IV, 12. 10 | with Community Directive 37/2001/ΕΚ, which arranges
53 IV, 12. 10 | of 8th November 2005.~Law 37/17 August 2006 entered into
54 IV, 12. 10 | 2002 with Directive 2001/37/CE;~ ~Law 332/11/2005, ratifying
|
|
| |
